drugset / Trial / NCT06961617
Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single center and open-label study to determine the safety and efficacy of mRNA HBV-TCR redirected T-cells in HBV-related HCC who are not amenable to/failed conventional treatment.
Timeline
- Start
- 2024-06-01
- Primary completion
- 2027-12-01
- Completion
- 2028-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LioCyx-M | Cell therapy | 5e+06 cells/kg | Intravenous |
| Subject | LioCyx-M | Cell therapy | 1e+07 cells/kg | Intravenous |